The MD Anderson Symptom Inventory for brain tumor (MDASI-BT) is a site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-BT also assesses 9 symptoms specific to brain tumors:
- weakness on one side of the body
- difficulty understanding
- difficulty speaking
- difficulty concentrating
- problems with vision
- change in appearance
- change in bowel pattern (diarrhea or constipation)
Order the MDASI-BT
- Purpose: To assess the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by brain tumor and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.67 to 0.91
Click on a linked language to view a sample in PDF format.
Don't see a language you need? Contact us at firstname.lastname@example.org.
|Psychometrically and Linguistically Validated||Linguistically Validated|
Chinese (Traditional - Hong Kong)
In response to the FDA's 2009 guidance for the pharmaceutical industry on the use of PRO measures in medical product development to support labeling claims, we have prepared a MDASI User's Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-BT. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Armstrong TS, Mendoza T, Gning I, et al. Validation of the M. D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol 80(1): 27-35, 2006.
Armstrong TS, Vera-Bolanos E, Acquaye A, et al. Impact of recall period on primary brain tumor patient's self-report of symptoms. Neurooncol Pract 1(2): 55-63, 2014.
Armstrong TS, Cohen M, Eriksen L, Cleeland C. Content validity of self-report measurement instruments: an illustration from the development of the brain tumor module of the M. D. Anderson Symptom Inventory. Oncol Nurs Forum 32(3): 669-676, 2005.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 2000; 89:1634-1646.
Vera-Bolanos E, Acquaye A, Mendoza T, et al. Evaluation of the utility of the EQ-5D and MDASI-BT in primary brain tumor patients [abstract]. Society for Neuro-Oncology 20th Annual Scientific Meeting and Education Day, San Antonio TX, Nov 19-22, 2015. Neuro-oncol 17(Suppl 5): v193, 2015; Abstract #QOL-25.
Tanaka S, Sato I, Takahashi M, et al. Validation study of the Japanese version of M. D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) [abstract]. Society for Neuro-Oncology 20th Annual Scientific Meeting and Education Day, San Antonio TX, Nov 19-22, 2015. Neuro-oncol 17(Suppl 5): v193, 2015; Abstract #QOL-24.
Gning I, Armstrong TS, Wefel JS, Acquaye A, Vera-Bolanos E, Mendoza TR, Gilbert MR, Cleeland CS. Validation of the M. D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Caregiver version. [abstract]. The University of Texas MD Anderson Cancer Center, Division of Internal Medicine Research Retreat, Houston TX, May 24, 2012.
Pollom EL, Fujimoto D, Wynne J, et al. Phase 1/2 trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent and adjuvant temozolomide in newly diagnosed supratentorial glioblastoma: health-related quality of life results. Int J Radiat Oncol Biol Phys 98(1): 123-130, 2017.
Armstrong TS, Vera-Bolanos E, Acquaye AA, et al. The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro Oncol 18(2): 252-260, 2016.
Armstrong TS, Wefel JS, Wang M, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 31(32): 4076-4084, 2013.
Lin L, Chiang HH, Acquaye AA, et al. Uncertainty, mood states, and symptom distress in patients with primary brain tumors: analysis of a conceptual model using structural equation modeling. Cancer 119(15): 2796-2806, 2013.
Armstrong TS, Wefel JS, Gning I, et al. Congruence of primary brain tumor patient and caregiver symptom report. Cancer 118(20): 5026-5037, 2012.
Armstrong TS, Vera-Bolanos E, Gning I, et al. The impact of symptom interference using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer 117(14): 3222-3228, 2011.
Armstrong TS, Gning I, Mendoza TR, et al. Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage 37(3): 331-340, 2009.
Every MDASI Module Contains...
All 13 MDASI core symptoms
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
All 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
Cancer patients with central nervous system tumors are a unique group because of the neurological nature of their symptoms, which affect their functional abilities, social interactions, and emotional well-being—and thus their quality of life.
Terri S. Armstrong, Ph.D., ANP-BC
Senior Investigator, NCI